Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
View in:
PubMed
subject areas
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Apolipoproteins B
Cholesterol, LDL
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Hypercholesterolemia
Lipoprotein(a)
Molecular Targeted Therapy
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases